Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant.

Abstract

BACKGROUND:

Growing evidence supports a genetic link between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). Interesting data demonstrated that both the major NAFLD risk polymorphisms such as the I148M polymorphism in the patatin like phospholipase containing domain 3 (PNPLA3) and the E167K allele in the transmembrane 6 superfamily member 2 gene (TM6SF2) affect renal function. Recently the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene has been recognized as a novel genetic variant involved in NAFLD pathophysiology. In particular, it has been showed the protective effect of the rs72613567:TA variant of this gene against liver damage both in adults and children.

AIM:

To investigate the impact of the rs72613567:TA variant of the HSD17B13 gene on estimated glomerular filtration rate (eGFR) in obese children.

METHODS:

We enrolled 684 obese children (mean age 10.56 ± 2.94 years; mean BMI-SDS 2.98 ± 0.78) consecutively attending our Obesity Clinic. All the patients underwent a careful clinical assessment and a comprehensive biochemical evaluation. To detect hepatic steatosis, a liver ultrasound was performed. NAFLD was defined by ultrasound detected liver steatosis and/or alanine aminotransferase (ALT) levels > 40 IU/L. The study population was divided on the basis of the NAFLD presence. Genotyping for the rs72613567:TA variant of the HSD17B13 gene in all the enrolled subjects was also made.

RESULTS:

Patients carrying the HSD17B13 rare A allele showed higher eGFR levels compared with homozygous patients both among subjects with and without NAFLD. A general linear model confirmed a direct and significant association of eGFR values with HSD17B13 genotype independently of PNPLA3 and TM6SF2 polymorphisms both in patients with and without NAFLD. A comparison of regression line confirmed the influence of HSD17B13 genotype on the relationship between eGFR and age both among patients with and without NAFLD. Homozygous patients for HSD17B13 genotype with NAFLD showed a significantly higher decline of eGFR with the increase of the age compared with the patients with NAFLD carrying the HSD17B13 rare A allele (P value for intercepts = 0.005; P value for slopes = 0.94). The same effect was observed among patients without NAFLD (P value for intercepts = 0.0012; P value for slopes = 0.87).

CONCLUSION:

Carriers of the HSD17B13 rare A allele showed higher eGFR levels than homozygous subjects both among subjects with and without NAFLD and independently of PNPLA3 I148M and TM6SF6 E167K polymorphisms.

• Authors: Anna Di Sessa, Giuseppina Rosaria Umano, Grazia Cirillo, Antonio Paride Passaro, Valentina Verde, Domenico Cozzolino, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia Del Giudice
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 26 Issue 36 Pg. 5474-5483 (Sep 28 2020) ISSN: 2219-2840 [Electronic] United States
• PMID: 33024398 (Publication Type: Journal Article)
• Copyright: ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Chemical References

• Membrane Proteins
• Alanine Transaminase
• Lipase

Topics

• Adolescent
• Adult
• Alanine Transaminase
• Child
• Genetic Predisposition to Disease
• Humans
• Kidney
• Lipase (genetics)
• Liver (diagnostic imaging)
• Membrane Proteins (genetics)
• Non-alcoholic Fatty Liver Disease (diagnosis, genetics)
• Polymorphism, Single Nucleotide